<DOC>
	<DOCNO>NCT01740791</DOCNO>
	<brief_summary>The goal study assess safety , tolerability , antiviral activity pharmacokinetics GS-5816 HCV treatment naïve subject genotypes 1-6 .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Antiviral Activity GS-5816 Subjects With Chronic HCV Infection</brief_title>
	<detailed_description>Administration GS-5816 limit 3 consecutive day minimize potential development resistance . All subject monitor 48 week post-dose determine persistence viral mutation . Twelve cohort plan examination ; within cohort subject receive QD dose GS-5816 safety , antiviral activity pharmacokinetic assessment evaluate specified time-points study</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>HCV treatmentnaïve adult subject ( 1865 year age ) chronic HCV infection plasma HCV RNA ≥ 5 log10 IU/mL screen Agree use protocol define precaution pregnancy Chronic liver disease nonHCV etiology ( e.g. , hemochromatosis , Wilson 's disease , α1 antitrypsin deficiency , cholangitis ) Evidence cirrhosis Evidence current drug abuse Screening laboratory result outside protocol specify requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Genotype 3</keyword>
	<keyword>Genotype 4</keyword>
	<keyword>Genotype 5</keyword>
	<keyword>Genotype 6</keyword>
	<keyword>Liver Disease</keyword>
</DOC>